https://www.selleckchem.com/pr....oducts/beta-lapachon
001). CBU lymphocyte content and a prior transplant were associated with chimerism (P less then .01). Safety was acceptable 3 patients developed mild cytokine release syndrome, 2 had grade 1 and 2 had grade 4 graft-versus-host disease. Seven responders and 6 nonresponders (after additional therapy) received subsequent transplant; 5 are alive (follow-up, 5-47 months). The most common cause of death for nonresponders was disease progression, whereas for responders it was infection. CB-derived adoptive cell therapy is feasible and e
Like
Comment
Share
